Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
about
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases[Efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II with and without comparison to placebo: systematic review and meta-analysis].Murine neural stem cells model Hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved.Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.Child with Mongolian spots and dysostosis multiplex.Changes in gait pattern as assessed by the GAITRite™ walkway system in MPS II patients undergoing enzyme replacement therapy.Heparin cofactor II thrombin complex as a biomarker for mucopolysaccharidosis: Indian experience.Health-Related Quality of Life in Patients with MPS II.The management of children with Hunter syndrome - a case study.Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II.MPS II: adaptive behavior of patients and impact on the family system.Restoring functional neurofibromin by protein transduction.
P2860
Q24186164-914362B1-0570-4E0C-A8C7-ACF1BCF7D61CQ24201176-14F11403-2A2F-4A4A-875E-CD1107F0B728Q24235224-DA97917C-D5DA-4806-A42C-625152601577Q24241548-59AB1CCE-0488-48A3-B838-5F7C24E3BFDCQ34714510-87D8476D-C358-4138-AB0F-11144C3F7244Q35427537-B35632E7-BA3F-40EF-9657-922628E2A35DQ37357050-E560FFB8-C56E-4622-89F5-15E7E8EF8408Q37494846-B2768119-453A-4F0D-8EE0-0C1329301017Q38040710-CD9E4B32-C10E-4E39-B1E2-7A172BD20E57Q39826043-1B014C61-3BE7-4FAF-8D7E-9DB558FC8A46Q44529811-2C9A021F-2514-413C-A4B7-A8DF5AFB1525Q45910448-325B488F-2BD8-4F5F-9953-CF713DFF343DQ45962203-C32DBAE7-FE24-42E7-87D3-861150F390C5Q46094102-CC05B3F8-35D8-4D24-AF19-D666841B1125Q47351924-826C3006-3B0D-4245-B75A-D38294F82165Q50356355-A3251A9C-F5DC-4AD2-B074-35C8EB27CEE2Q52579455-B5C8053D-EC88-4FE0-AC2E-1C4CCA4FA74D
P2860
Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enzyme replacement therapy wit ...... mucopolysaccharidosis type II.
@en
Enzyme replacement therapy wit ...... mucopolysaccharidosis type II.
@nl
type
label
Enzyme replacement therapy wit ...... mucopolysaccharidosis type II.
@en
Enzyme replacement therapy wit ...... mucopolysaccharidosis type II.
@nl
prefLabel
Enzyme replacement therapy wit ...... mucopolysaccharidosis type II.
@en
Enzyme replacement therapy wit ...... mucopolysaccharidosis type II.
@nl
P2860
P1433
P1476
Enzyme replacement therapy wit ...... mucopolysaccharidosis type II.
@en
P2093
J Edmond Wraith
P2860
P356
10.1111/J.1651-2227.2008.00661.X
P407
P577
2008-04-01T00:00:00Z